(NP (NP-COOD (NP (NN BCL-6)) (CC and) (NP (NP (DT the) (JJ molecular) (NN pathogenesis)) (PP (IN of) (NP (NN B-cell) (NN lymphoma))))) (. .))
(S (NP-SBJ (NP (DT The) (NNS results)) (VP (VBN presented) (NP (-NONE- *)))) (VP (VBP identify) (NP (NP (DT the) (JJ first) (JJ genetic) (NN lesion)) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (NP (NN DLCL)) (, ,) (NP (NP (DT the) (ADJP (RBS most) (RB clinically) (JJ relevant)) (NN form)) (PP (IN of) (NP (NN NHL))))))))) (. .))
(S (SBAR (IN Although) (S (NP-SBJ (NP (DT no) (NN proof)) (PP (-NONE- *ICH*-65))) (ADVP-TMP (RB yet)) (VP (VBZ exists) (PP-65 (IN of) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (DT these) (NNS lesions))) (PP (IN in) (NP (NN DLCL) (NN pathogenesis)))))))) (, ,) (NP-SBJ-COOD (NP (NP (DT the) (NN feature)) (PP (IN of) (NP (DT the) (NN BCL-6) (NN gene) (NN product)))) (, ,) (NP (NP (PRP$ its) (JJ specific) (NN pattern)) (PP (IN of) (NP (NN expression))) (PP (IN in) (NP (NN B) (NNS cells)))) (, ,) (CC and) (NP (NP (DT the) (NN clustering)) (PP (IN of) (NP (NNS lesions))) (VP (VBG disrupting) (NP (PRP$ its) (JJ regulatory) (NN domain))))) (ADVP (RB strongly)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NP (NN deregulation)) (PP (IN of) (NP (NN BCL-6) (NN expression)))) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NN DLCL) (NN development)))))))) (. .))
(S (NP-SBJ (NP (DT A) (ADJP (RBR more) (JJ precise)) (NN definition)) (PP (IN of) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN BCL-6))) (PP (IN in) (NP (ADJP-COOD (ADJP (JJ normal)) (CC and) (ADJP (JJ neoplastic))) (NN B-cell) (NN development)))))) (VP (VBZ is) (NP-PRD (NP (DT the) (NN goal)) (PP (IN of) (NP (NP (JJ ongoing) (NN study)) (PP (IN of) (NP (NP (JJ transgenic) (NNS mice)) (VP (VBN engineered) (NP-103 (-NONE- *)) (S (NP-SBJ (-NONE- *-103)) (VP-COOD (CC either) (VP (TO to) (VP (VB express) (NP (NN BCL-6)) (PP (IN under) (NP (JJ heterologous) (NNS promoters))))) (CC or) (VP (VBG lacking) (NP (NN BCL-6) (NN function)) (PP (JJ due) (TO to) (NP (VBN targeted) (NNS deletions))))))))))))) (. .))
(S (PP (IN In) (NN addition) (TO to) (S (NP-SBJ (-NONE- *-28)) (VP (VBG contributing) (PP (TO to) (NP (NP (DT the) (NN understanding)) (PP (IN of) (NP (NN DLCL) (NN pathogenesis)))))))) (, ,) (NP-SBJ-28 (NP (DT the) (NN identification)) (PP (IN of) (NP (NN BCL-6) (NNS lesions)))) (VP (MD may) (VP (VB have) (NP (JJ relevant) (JJ clinical) (NNS implications)))) (. .))
(S (NP-SBJ (NN DLCL)) (VP (VBP represent) (NP (NP (DT a) (JJ heterogeneous) (NN group)) (PP (IN of) (NP (NP (NNS neoplasms)) (SBAR (WHNP-29 (WDT which)) (S (NP-SBJ-30 (-NONE- *T*-29)) (VP (VBP are) (VP (VBN treated) (NP (-NONE- *-30)) (ADVP (RB homogeneously)) (PP (IN despite) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (NP (QP (RB only) (CD 50)) (NN %)) (PP (IN of) (NP (NNS patients)))) (VP (VBP experience) (NP (JJ long-term) (JJ disease-free) (NN survival)))))))))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Schneider)) (ADVP (FW et) (FW al.))) (NP-TMP (CD 1990))) (-RRB- -RRB-))) (. .))
(S (NP-SBJ (DT The) (NN fact) (SBAR (IN that) (S (NP-SBJ (NN BCL-6) (NNS rearrangements)) (VP (VBP identify) (NP (NP (ADJP (ADVP-COOD (ADVP (RB biologically)) (CC and) (ADVP (RB clinically))) (JJ distinct)) (NNS subsets)) (PP (IN of) (NP (NN DLCL)))))))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (DT these) (NNS lesions)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ useful)) (PP (IN as) (NP (NNS markers))) (PP (IN in) (NP (NP (NN selection)) (PP (IN of) (NP (JJ differential) (JJ therapeutic) (NNS strategies))) (PP (VBN based) (PP (IN on) (NP (JJ different) (NN risk) (NNS groups))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-31 (DT the) (NN BCL-6) (NNS rearrangements)) (VP (MD can) (VP (VB be) (VP (VBN used) (NP-32 (-NONE- *-31)) (S (NP-SBJ (-NONE- *-32)) (VP (TO to) (VP (VP-COOD (VP (VB identify) (NP (-NONE- *RNR*-33))) (CC and) (VP (VB monitor) (NP (-NONE- *RNR*-33)))) (NP-33 (DT the) (JJ malignant) (NN clone)) (PP (IN with) (NP (JJ sensitive) (JJ PCR-based) (NNS techniques))))))))) (. .))
(S (SBAR (IN Since) (S (NP-SBJ-35 (JJ clinical) (NN remission)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (NP (-NONE- *-35)) (PP (IN in) (NP (NP (DT a) (JJ significant) (NN fraction)) (PP (IN of) (NP (NN DLCL) (NNS cases)))))))))) (, ,) (NP-SBJ (DT these) (NNS markers)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (JJ critical) (NNS tools)) (PP (IN for) (NP-COOD (NP (NP (JJ sensitive) (NN monitoring)) (PP (IN of) (NP (JJ minimal) (JJ residual) (NN disease)))) (CC and) (NP (NP (JJ early) (NN diagnosis)) (PP (IN of) (NP (NN relapse)))))))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP Gribben)) (ADVP (FW et) (FW al.))) (NP-TMP (CD 1993))) (-RRB- -RRB-)))) (. .))
